Literature DB >> 10400759

Herpes simplex virus latency-associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency.

S K Thomas1, G Gough, D S Latchman, R S Coffin.   

Abstract

Herpes simplex virus types 1 and 2 (HSV1 and HSV2) enter and reactivate from latency in sensory neurons, although the events governing these processes are little understood. During latency, only the latency-associated transcripts (LATs) are produced. However, although the LAT RNAs were described approximately 10 years ago, their function remains ambiguous. Mutations affecting the LATs have minimal effects other than a small reduction in establishment of and reactivation from latency in some cases. Mutations in putative LAT-contained open reading frames (ORFs) have so far shown no effect. The LATs consist of a large species from which smaller (approximately 2 kb), nuclear, nonlinear LATs which are abundant during latency are spliced. Thus, translation of ORFs in these smaller LATs would not usually be expected to be possible, and if expressed at all, their expression might be tightly regulated. Here we show that deregulated expression of the largest HSV1 2-kb LAT-contained ORF in various cells of neuronal and nonneuronal origin greatly enhances virus growth in a manner specific to HSV1-the HSV1 LAT ORF has no effect on the growth of HSV2. Similar results of enhanced growth were found when the HSV1 LAT ORF was constitutively expressed from within the HSV1 genome. The mechanism of LAT ORF action was strongly suggested to be by substituting for deficiencies in immediate-early (IE) gene expression (particularly ICP0), because deregulated LAT ORF expression, as well as enhancing wild-type virus growth, was also found to allow efficient growth of viruses with mutations in ICP0 or VMW65. Such viruses otherwise exhibit considerable growth defects. IE gene expression deficiencies are often the block to productive infection in nonpermissive cells and are also evident during latency. These results, which we show to be protein- rather than RNA-mediated effects, strongly suggest a function of the tightly regulated expression of a LAT ORF-encoded protein in the reactivation from HSV latency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400759      PMCID: PMC112746          DOI: 10.1128/JVI.73.8.6618-6625.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  A 348-base-pair region in the latency-associated transcript facilitates herpes simplex virus type 1 reactivation.

Authors:  D C Bloom; J M Hill; G Devi-Rao; E K Wagner; L T Feldman; J G Stevens
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

2.  Evidence that two latency-associated transcripts of herpes simplex virus type 1 are nonlinear.

Authors:  T T Wu; Y H Su; T M Block; J M Taylor
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

3.  Analysis of the 2-kilobase latency-associated transcript expressed in PC12 cells productively infected with herpes simplex virus type 1: evidence for a stable, nonlinear structure.

Authors:  E Rødahl; L Haarr
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

4.  The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Expression of a herpes simplex virus 1 open reading frame antisense to the gamma(1)34.5 gene and transcribed by an RNA 3' coterminal with the unspliced latency-associated transcript.

Authors:  M Lagunoff; B Roizman
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

6.  The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency.

Authors:  G C Perng; E C Dunkel; P A Geary; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  A 371-nucleotide region between the herpes simplex virus type 1 (HSV-1) LAT promoter and the 2-kilobase LAT is not essential for efficient spontaneous reactivation of latent HSV-1.

Authors:  G C Perng; S M Slanina; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

8.  The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript.

Authors:  G C Perng; H Ghiasi; S M Slanina; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Identification of gene products encoded by the latency-related gene of bovine herpesvirus 1.

Authors:  A Hossain; L M Schang; C Jones
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections.

Authors:  X Chen; M C Schmidt; W F Goins; J C Glorioso
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  31 in total

1.  Enhancer and long-term expression functions of herpes simplex virus type 1 latency-associated promoter are both located in the same region.

Authors:  H Berthomme; J Thomas; P Texier; A Epstein; L T Feldman
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy.

Authors:  Laila Samady; Emanuela Costigliola; Luci MacCormac; Yvonne McGrath; Steve Cleverley; Caroline E Lilley; Jill Smith; David S Latchman; Benny Chain; Robert S Coffin
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  The stable 2.0-kilobase intron of the herpes simplex virus type 1 latency-associated transcript does not function as an antisense repressor of ICP0 in nonneuronal cells.

Authors:  Edward A Burton; Chang-Sook Hong; Joseph C Glorioso
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 4.  Herpes simplex virus latency-associated transcript gene function.

Authors:  Jennifer R Kent; Wen Kang; Cathie G Miller; Nigel W Fraser
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

Review 5.  Peculiarities of herpes simplex virus (HSV) transcription: an overview.

Authors:  Július Rajcáni; Vojvodová Andrea; Rezuchová Ingeborg
Journal:  Virus Genes       Date:  2004-04       Impact factor: 2.332

6.  Different modes of herpes simplex virus type 1 spread in brain and skin tissues.

Authors:  Yael Tsalenchuck; Tomer Tzur; Israel Steiner; Amos Panet
Journal:  J Neurovirol       Date:  2014-01-10       Impact factor: 2.643

7.  Identification of herpes simplex virus type 1 proteins encoded within the first 1.5 kb of the latency-associated transcript.

Authors:  Gail Henderson; Tareq Jaber; Dale Carpenter; Steven L Wechsler; Clinton Jones
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

8.  A protein encoded by the herpes simplex virus (HSV) type 1 2-kilobase latency-associated transcript is phosphorylated, localized to the nucleus, and overcomes the repression of expression from exogenous promoters when inserted into the quiescent HSV genome.

Authors:  S K Thomas; C E Lilley; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  Analysis of protein expression from within the region encoding the 2.0-kilobase latency-associated transcript of herpes simplex virus type 1.

Authors:  M Lock; C Miller; N W Fraser
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

10.  Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle.

Authors:  Guey-Chuen Perng; Clinton Jones
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.